|

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

RECRUITINGPhase 2Sponsored by University of California, San Francisco
Actively Recruiting
PhasePhase 2
SponsorUniversity of California, San Francisco
Started2023-08-07
Est. completion2026-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05851391

Summary

RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age ≥18 years old
2. Non-traumatic, out-of-hospital cardiac arrest
3. Comatose on admission - defined as not following commands
4. Return of spontaneous circulation (ROSC) within less than 45 minutes
5. Admission to the intensive care unit
6. Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous

EEG monitoring within 7 days from ROSC

Exclusion Criteria:

1. Acute cerebral hemorrhage or infarction
2. Pregnancy
3. Prisoners

Conditions8

Anoxia-Ischemia, CerebralAnoxic-Ischemic EncephalopathyHeart ArrestHeart DiseaseHypoxia-Ischemia, BrainRefractory Status EpilepticusSeizuresStatus Epilepticus

Interventions2

Burst Suppression EEG Target Intravenous AnesthesiaSeizure Suppression EEG Target Intravenous Anesthesia

Locations1 site

Zuckerberg San Francisco General Hospital
San Francisco, California, 94110
Edilberto Amorim, MD

Find trials near these locations

Heart Disease trials in San FranciscoAll trials in California

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.